Nanexa

The authors of the abstract are Karthik Ramasamy, Marie von Lilienfeld-Toal, Christopher Maisel, Bengt Gustavsson, Kristine Bäck, Axel Glasmacher and Xavier Leleu.

"It is now evident to everyone that we have taken the first step towards building a health economical file for NEX-20 for the treatment of multiple myeloma", says David Westberg, CEO of Nanexa. "A so called "Systematic Literature Review" is one of the first steps in the advanced process of building a health economic base for the reimbursement application you have to submit to payors at the time the new drug gets its regulatory approval. In short, our study shows that patients’ adherence to their drug treatment against multiple myeloma might be suboptimal. More research is needed, however, as published studies so far often show variations when you compare them with each other."